ACHE and Alzheimer disease: Acetyl cholinesterase inhibitors (AChEIs) remain the mainstay of pharmacotherapy whose wide clinical use is largely justified by 3- to 6-month improvements in cognitive and global function in Alzheimer's disease with a Cochrane review estimating a 1.37 (95% CI 1.13, 1.61) Mini-Mental State Examination (MMSE) score improvement at 6 months after AChEI initiation [1].